Based on recent advances, sodium glucose transporter (SGLT) 2 inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists are attracting attention (Palmer et al., 2021; Sattar et al., 2021); however, standard care for DKD in type 1 diabetes (T1D) and type 2 diabetes (T2D) for the past two decades has been renin-angiotensin aldosterone system (RAS) blockade using angiotensin-converting enzyme inhibitors (ACEis) or angiotensin II receptor blockers (ARBs) (Frimodt-Moller et al., 2020). Here, ACE is linked to type 2 diabetes mellitus.